We compared the antigen-specific antibody isotypes and lymphokine secretion by CD4+ T cells in BALB/c mice immunized intradermally with either Escherichia coli 13-galactosidase (13-gal) 
,8-gal in a cytomegalovirus-based expression vector (pCMVLacZ). pCMV-LacZ induced mainly IgG2a, whereas 13-gal in saline or alum induced IgGI and IgE 1-gal-specific antibodies. In addition, splenic CD4+ T helper (Th) cells isolated from pDNA-immunized mice secreted interferon-y but not interleukin (IL)-4 and IL-5, whereas Th cells from 13-gal-injected mice secreted IL-4 and IL-5 but not interferon-y after in vitro stimulation with antigen. Together these data demonstrate that pDNA immunization induced a T helper type 1 (Thl) response, whereas protein immunization induced a T helper type 2 (Th2) response to the same antigen. Interestingly, priming of mice with pCMV-LacZ prevented IgE antibody formation to a subsequent i.p. 13-gal in alum injection. This effect was antigen-specific, because priming with pCMV-LacZ did not inhibit IgE anti-ovalbumin antibody formation. Most importantly, intradermal immunization with pCMV-LacZ (but not pCMV-OVA) of 13 -gal in alum-primed mice caused a 66-75% reduction of the IgE anti-,B-gal titer in 6 weeks. Also, pCMV-LacZ induced specific IgG2a antibody titers and interferon-y secretion by Th cells in the 13-gal in alum-primed mice. The data demonstrate that gene immunization induces a Th, response that dominates over an ongoing proteininduced Th2 response in an antigen-specific manner. This suggests that immunization with pDNA encoding for allergens may provide a novel type of immunotherapy for allergic diseases. inflammatory reaction at the injection site despite the induction of a cellular (cytotoxic lymphocytes) and humoral (IgG antibodies) immune response to the encoded antigens. When we analyzed the specific IgG antibodies for their subclass distribution, we found that the IgG antibodies were almost entirely of the IgG2a subclass. This was surprising because mice immunized with protein antigens, in contrast to viral or bacterial antigens, produce predominantly IgGl (7) and often IgE (8) antibodies. IgG2a antibody formation is dependent on interferon-y (IFN-,y) as an IgM-to-IgG2a switch factor and is believed to be typical for a T helper (Th) type 1 (Th1) response (9) . In contrast, IgGl and particularly IgE antibody production depends on interleukin (IL)-4 secreted by Th2 cells (10) . To This results in both a cellular and humoral immune response to the antigen (1-6). Immunization with pDNA encoding an antigen (gene vaccination) has generated great interest by investigators searching for better vaccination methods, especially for inducing cellular immune responses to viral infections, including HIV-1 (4). Recently, we showed that i.d. injection of pDNA encoding influenza nucleoprotein (NP) or Escherichia coli ,B-galactosidase ((3-gal) in a cytomegalovirus (CMV)-based expression vector (pCMV-NP and pCMVLacZ, respectively) led to prolonged expression of intracellular antigen by dermal keratinocytes, fibroblasts, and cells with the morphology of Langerhans cells and macrophages (6) . We also showed that expression of these antigens does not cause an METHODS Mice. Female BALB/c mice were purchased from The Jackson Laboratory, maintained in the University of California, San Diego, Animal Facility accredited by the American Association for the Accreditation of Laboratory Animal Care, and used at 6-8 weeks of age.
pDNA Preparation. The construction pCMV-based vectors has been described (6) . pCMV-LacZ contains the CMV IEl promotor-intron, the simian virus 40 t-intron, the E. coli LacZ cDNA, and the simian virus 40 polyadenylylation site. The pCMV-OVA vector encodes hen egg ovalbumin (OVA) cDNA, and the plasmid backbone is identical to pCMV-LacZ. pDNA was purified using a Qiagen megaprep kit (Qiagen, Chatsworth, CA) and was stored at -20°C in 10 mM Tris.HCl/ 0.1 mM EDTA, pH 8.0. The endotoxin content was reduced by extraction with Triton X-114 (Sigma) to 0.5-5 ng per 1 mg of pDNA (11) The IgE anti-1-gal or anti-OVA antibodies were measured by a radioimmuno-allergosorbent test as described (12) . Briefly, 96-well polyvinyl plates were coated with 10 ,tg of 13-gal per ml of BBS (pH 9.2) for 1 hr at room temperature. The plates were washed, and nonspecific sites were blocked with 5% nonfat milk in BBS for 2 (13) . Three days before sacrifice, the mice were injected i.v. with 10 Ag of 1-gal in 50 ,lI of saline.
Spleens were removed and teased to prepare single-cell suspensions in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum. The cells were enriched for CD4+ T cells by treatment with monoclonal antibodies to CD8 and CD56 and complement as described (14) . This procedure resulted in removal of >95% of the 13 -gal in saline as a control for the effect of a booster injection of 13-gal in alum. As shown in Fig. 24 , mice primed with pDNA showed an increase from 5000 to 42,000 units/ml of IgG2a antibodies after injection of 13-gal in alum. Control mice primed with 1-gal in saline, which formed only minimal titers of IgG2a after the primary 13-gal injection, also formed almost no IgG2a after the 13-gal in alum booster injection. Injection of 13-gal in alum did induce IgGl antibody formation in the pDNA-primed mice (Fig. 2B) ; however, the titers were not as high as those in 13-gal in saline-primed mice. Boosting of pCMV-LacZ-primed mice with 13-gal in alum induced only minimal IgE antibody production over the 6-week observation period (Fig. 2C) . Injection of 13-gal in alum induced a large IgGl and also an IgE antibody response in the 13-gal in saline-primed control mice (Fig. 2C) . The IgE response reached a peak at 2 weeks and declined thereafter. The suppression of IgE anti-13-gal antibody formation in pCMVLacZ-primed mice after a booster injection of 13-gal in alum was antigen-specific. As shown in Fig; 2D , mice primed with pCMV-LacZ and injected with OVA in alum formed IgE antibodies to OVA with no increase in IgE antibodies to 1-gal. ± SE of four mice per group are shown. The differences in antibody titers at 2-6 weeks between pDNA-and protein-primed mice were statistically significant (P < 0.05).
At 4 weeks, the mean ± SE anti-OVA titer in the pDNAprimed mice was 2358 ± 581 cpm as compared with 2241 ± 338 cpm in naive mice, indicating that pDNA immunization had no nonspecific suppressive effect on IgE antibody production. The 13-gal-induced lymphokine secretion in vitro by splenic CD4+ T cells from these mice is shown in Fig. 3 , pCMV-LacZ immunization induced IgG2a antibody formation in the 1B-gal in alum-primed mice within 4 weeks, the titer being similar to the primary pDNA response (Fig. 1) . The low IgG2a titers in the 13-gal in alum control mice decreased over the same time period. Injection of pCMV-LacZ also induced an increase in IgGl antibody formation, whereas the IgGl titer decreased slightly in the control mice. Most interestingly, and in contrast to the 13-gal in saline-injected control mice, pCMV-LacZ, whether injected i.d. or administered with the tyne device (data not shown), induced a 66% (Fig. 3C ) and a 75% (Fig. 3D ) decrease of the IgE antibody titer over a 6-week period in two different experiments. This was not due to the effect of competition for antigen by IgG antibodies in the radioimmuno-allergosorbent assay because removal of IgG2a, IgG2b, and IgG3 and 90% of the IgGl in pooled sera from the four mice in each group and retesting the absorbed sera for IgE did not result in qualitatively different results. Also, the suppressive effect on IgE antibody formation was antigen-specific because injection of pCMV-OVA did not result in a decrease of IgE anti-,3-gal antibody formation (Fig. 3D ).
Six weeks after the pCMV-LacZ booster injection, the mice were killed, and the 3-gal-induced IFN--y, IL-4, and IL-S secretion by splenic CD4+ T cells was determined. As shown in Table 1 (experiment G), CD4+ T cells from the 13-gal in alum-primed and pCMV-LacZ-boosted mice secreted IFN-'y in amounts similar to the pCMV-LacZ-primed mice (experiment B). The cells secreted IL-4 similar to 13-gal in alum control mice, but only one-third of the amounts of IL-S (experiment G versus D). The Ig isotypes of the antibodies and the lymphokine secretion by the Th cells from the 13-galprimed and pDNA-boosted mice indicates that priming of mice with 13-gal in alum did not prevent a secondary Th1 response (IgG2a antibodies and IFN--y secretion) (18) .
The suppressive effect of pCMV-LacZ immunization on IgE anti-83-gal antibody production was not only antigen-specific but also selective for the IgE isotype. Priming of mice with pCMV-LacZ prevented IgE formation and diminished IgGl anti-,B-gal antibody production following a secondary 13-gal in alum injection. Similarly, boosting 13-gal in alum-primed mice with pCMV-LacZ resulted in an increase of the IgGl antibody titer whereas it caused a 66-75% decrease in the 13-gal-specific IgE antibody formation 6 weeks after pDNA injection. Although IgGl antibody production, like IgE production, is typical for a Th2 cell response (9) , IgGl formation is much less dependent on, or in some instances even independent of, the requirement for IL-4. Injection of anti-IL-4 antibodies inhibits IgE but not IgGl formation in mice (19) . Although the mechanism of the selective down-regulation of IgE antibody production is not known, it is probably due to the induction of new antigen-specific Th, cells that are able to down-regulate the differentiation of new Th2 cells as has been shown in other systems (9) . Furthermore, IgE has a very short serum half-life (20) , which is likely responsible for the rapid decrease of the IgE titer once IgE synthesis is suppressed by the secondary pDNA immunization. Whether the decrease of specific IgE antibodies in the serum will also be reflected in a decrease of anaphylactic reactions after antigen challenge remains to be determined.
The reasons why pDNA immunization leads to a Th, response and protein immunization leads to a Th2 response are presently not understood. As we have shown previously (6) , the pDNA is taken up by various types of cells in the skin which then produce the gene product. Therefore, 13-gal becomes an intracellular antigen that can be processed and presented on major histocompatibility class I molecules like other intracellular antigens (21) . Major histocompatibility complex class I-presented (3-gal thus may preferentially induce CD8+ antigen-specific T cells (6) secreting IFN-y, as well as other lymphokines that promote Th1 cell differentiation and downregulate the differentiation of CD4+ Th2 cells. Another possibility is that pDNA uptake induces IL-12 secretion by antigen-presenting cells and/or keratinocytes in the skin. Keratinocytes, as well as macrophages, have been shown to produce IL-12 (22, 23) and IL-12 induces IFN--y secretion which plays an important role in Tho-to-Th1 cell differentiation. Such a model would be similar to infection of the skin with herpes simplex virus, which also elicits a Th, response to the virus (24) . In a recent study, the immune response to intramuscular vaccination with pDNA encoding a herpes simplex virus glycoprotein was compared with the immune response to live or attenuated herpes simplex virus (5). All three immunization procedures elicited predominantly IgG2a antibodies and IFN-y-producing CD4+ T cells; however, the ratio of IgG2a to IgGl antibodies for pDNA-immunized animals was 3-and 6-fold higher than live or attenuated virus immunization, respectively. Although herpes simplex virus by itself induces a Th1 response, these experiments show that pDNA immunization is the most effective inducer of IgG2a antibodies to the viral glycoprotein.
The fact that a preexisting Th2 response to [3- (25) . Manipulations such as IFN-y injections that "switch" the Th2 to a Th, response in susceptible strains make such mice resistant to Leishmania infection (26) . A similar situation may occur in humans with some types of parasitic infections such as filariasis and in persons with allergies. Nonatopic humans form a Th, whereas atopic patients form a Th2 response to allergens (27) . Classical immunotherapy appears to slowly change the Th2 to a Thb response in the patients (28, 29) . However, the allergen must be injected subcutaneously over a long period of time. Furthermore, injection of native antigen as is used in conventional immunotherapy may cause severe anaphylactic reactions. Therefore, transfecting skin cells with pDNA encoding for allergens may be a safer and more efficient form of immunotherapy. Because pDNA remains in the transfected cells for a long time (6) , only a few injections of pDNA would be necessary. Furthermore, the fact that scratching the skin with a tyne applicator to which the pDNA was applied resulted in the same transfection of the skin cells as i.d. injection of pDNA could make this form of immunotherapy easily applicable and cost effective. For these reasons it will be crucial to investigate in primates whether immunization with pDNA-encoding allergens will induce IgG antibodies and down-regulate any preexisting or new IgE anti-allergen antibody formation. This experiment will help to determine whether allergen gene vaccination may be applicable for the treatment of allergic disorders in humans.
